Benzinga | May 6, 2021 08:48AM EDT

Morgan Stanley Maintains Overweight on Neurocrine Biosciences, Lowers Price Target to $116

Morgan Stanley maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and lowers the price target from $125 to $116.